Testing Atezolizumab and Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma
Status:
Recruiting
Trial end date:
2022-10-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well atezolizumab works in treating patients with alveolar
soft part sarcoma that has not been treated, has spread from where it started to other places
in the body (advanced) and cannot be removed by surgery (unresectable). Atezolizumab works by
unblocking the immune system, allowing the immune system cells to recognize and then attack
tumor cells. Bevacizumab works by controlling the growth of new blood vessels. Giving
atezolizumab and bevacizumab may shrink the cancer.